Pharmaceuticals
Canada Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
Canada's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $1.46 Bn in 2022 and is estimated to expand at a CAGR of 7.1% from 2022 to 2030 and will reach $2.52 Bn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate, a result of government initiatives. The market is segmented by Drug class and by distribution channel. Some key players in this market are Abbott Laboratories, Adamis Pharmaceuticals Corporation, Almirall, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva Canada Limited, and others.
Buy Now
Canada Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Executive Summary
Canada's COPD therapeutics market was valued at $1.46 Bn in 2022 and is estimated to expand at a CAGR of 7.1% from 2022-30 and reach $2.52 Bn in 2030. Chronic obstructive pulmonary disease (COPD) is a chronic condition characterized by shortness of breath, cough, and sputum production. While signs of the disease do not commonly develop in those under the age of 55, lung alterations begin many years earlier. COPD is a catch-all term for a variety of respiratory disorders, including chronic bronchitis and emphysema. COPD deteriorates gradually over time. More frequent exacerbations, additional reductions in airflow, and earlier death are all connected with increasing disease severity. Shortness of breath limits people's activity levels and lowers their quality of life as the disease progresses.
Many people take their breathing for granted. In Canada, however, 3.8 Mn people over the age of one have asthma, and 2.0 Mn have chronic obstructive pulmonary disease (COPD), both of which can impair a person's capacity to breathe. People suffering from asthma or COPD may find it difficult to participate in daily life, school, work, and social activities. There is also a collective consequence in terms of missed productivity and healthcare expenses, especially given the rising prevalence of both asthma and COPD.
Market Dynamics
Market Growth Drivers
COPD is a major health issue in Canada, with a significant portion of the population affected by the disease. According to the Lung Association, an estimated 3 Mn Canadians are living with COPD, and the disease is responsible for approximately 10% of all deaths in the country. This growing prevalence of COPD is expected to drive the demand for COPD therapeutics in Canada. Combination therapy with bronchodilators and corticosteroids is often used to improve symptom control and reduce exacerbations in patients with COPD. The global COPD therapeutics market is expected to be driven by the increasing demand for combination therapies. This trend is expected to be reflected in the Canada market as well. The introduction of new drugs for the treatment of COPD is also expected to drive the growth of the COPD therapeutics market in Canada. For example, in 2019, Health Canada approved Trelegy Ellipta, a triple combination therapy for the treatment of COPD. The approval of new drugs is expected to expand the options for patients and improve outcomes. The Canadian government has also taken initiatives to address the growing burden of COPD. For example, the Canadian Thoracic Society has developed guidelines for the management of COPD, and the government has implemented policies aimed at reducing smoking rates, which is a major risk factor for COPD. These initiatives are expected to increase awareness of COPD and drive demand for COPD therapeutics in Canada.
Market Restraints
The cost of COPD treatment in Canada can be quite high, particularly for patients who require combination therapy or newer medications. This can make it difficult for some patients to access the treatment they need, particularly those who do not have adequate health insurance coverage. COPD is a chronic disease that requires long-term management, and adherence to treatment can be a challenge for some patients. This can be due to a variety of factors, including forgetfulness, difficulty using inhalers, or side effects from medication. Poor adherence to treatment can lead to worsened symptoms, increased risk of exacerbations, and poorer outcomes. Several key COPD medications have already lost patent protection or are set to lose patent protection in the coming years. This is expected to lead to increased competition from generic drugs, which could put pressure on prices and margins for manufacturers of branded medications. The regulatory environment for pharmaceuticals in Canada can be challenging, with lengthy approval processes and strict requirements for clinical trials. This can make it difficult for new drugs to enter the market, particularly for smaller companies with limited resources. Despite the availability of various medications for COPD, some patients may not respond well to current treatments or may experience side effects that limit their use. This highlights the need for continued research and development of new therapies for COPD.
Competitive Landscape
Key Players
- Abbott Laboratories
- Adamis Pharmaceuticals Corporation
- Almirall,
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim Pharmaceuticals
- Novartis
- Pfizer
- Teva Canada Limited
Healthcare Policies and Regulatory Landscape
Health Canada is the federal department responsible for overseeing the safety and effectiveness of pharmaceuticals and medical devices in Canada. All COPD medications must be approved by Health Canada before they can be marketed in the country. Health Canada also monitors the safety of drugs after they are on the market and can act if safety concerns arise.
Patented Medicine Prices Review Board (PMPRB) is an independent agency that regulates the prices of patented drugs in Canada. The PMPRB sets maximum prices that pharmaceutical companies can charge for their drugs, based on the value of the drug and the prices in other countries. The PMPRB also monitors the prices of drugs over time and can adjust the maximum price if necessary. Each Canadian province and territory have its own drug plan that provides coverage for prescription drugs. The drug plans vary by province and may cover different drugs, have different co-payments, and have different eligibility criteria. Pharmaceutical companies must negotiate with each province separately to have their drugs covered under the provincial drug plans.
Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent agency that provides evidence-based information about the effectiveness and cost-effectiveness of drugs and medical devices. CADTH evaluates drugs and makes recommendations to the provincial and territorial drug plans about whether the drugs should be covered and at what price.
Canadian Institutes of Health Research (CIHR) is the federal agency responsible for funding health research in Canada. CIHR provides funding for research related to COPD, including research into new treatments and therapies. This research can inform the development of new drugs and improve patient outcomes.
Overall, the healthcare policy and regulatory framework in Canada plays a critical role in shaping the Canada Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market. The policies and regulations aim to balance patient access to effective treatments with the need to control healthcare costs and promote safety and effectiveness.
Reimbursement Scenario
In Canada, healthcare is publicly funded and available to all citizens and permanent residents. However, some individuals may have private health insurance through their employer or purchase it independently. Private insurance plans may have different reimbursement policies and may not cover all of the same drugs as public drug plans. Many provincial drug plans require patients to pay a portion of the cost of their prescription drugs, known as a co-payment. The co-payment amount varies by province and may be based on income or other factors. Some provincial drug plans have tiered formularies, which categorize drugs into different tiers based on their cost and effectiveness. Drugs in higher tiers may have higher copayments or may not be covered at all.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Canada Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Segmentation
By Drug Class
- Bronchodilators: Bronchodilators are medications that help to relax the muscles around the airways, making it easier to breathe. These can be further classified as short-acting or long-acting bronchodilators
- Corticosteroids: Corticosteroids are anti-inflammatory medications that can help reduce swelling and inflammation in the airways. These can be used alone or in combination with bronchodilators
- Combination therapies: Combination therapies combine bronchodilators and corticosteroids in a single medication. These are often used for patients with more severe COPD
- Phosphodiesterase-4 inhibitors: Phosphodiesterase-4 inhibitors are medications that help to reduce inflammation and improve airflow in the lungs
- Others: Other medications that may be used to treat COPD include mucolytics, oxygen therapy, and vaccines for influenza and pneumococcal disease
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Insights10 will provide you with the reports within 10 key parameters which are:
- Market Overview
- Market Growth Drivers & Restraints
- Epidemiology of Disease Type
- Market Segmentation
- Market Share
- Competitive Landscape
- Key Company Profiles
- Healthcare Policies & Regulatory Framework
- Reimbursement Scenario
- Factors Driving Future Growth
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
(1).png)
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
- Establishing market drivers and trends
- Analyzing the regulatory landscape to understand future growth
- Market Segment based analysis to obtain revenue/volume
- Analyzing current needs and determining penetration to estimate the market
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
- Intelligent insights to take informed business decisions
- Qualitative, acute and result oriented market analysis
- Market size and forecasts from 2022 to 2030
- Opportunities for expansion and in-depth market analysis
- Segmentation and regional revenue forecasts
- Analysis of the market share and competitive landscape
- Strategic Recommendations to chart future course of action
- Comprehensive Market Research Report in PDF and PPT formats
Need more?
- Ask our analyst how this study was put together to learn more
- Discuss additional requirements as part of the free customisation
- Add more countries or regions to the scope
- Get answers to specific business questions
- Develop the business case to launch the product
- Find out how this report may influence your business revenue
Related reports (by category)
Pharmaceuticals
Canada Cough Remedies Market Analysis
Pharmaceuticals
Vietnam Cannabidiol (CBD) Market Analysis
Related reports (by geography)
Pharmaceuticals
Canada Infection Control Supplies Market Analysis
Pharmaceuticals
Canada Dermatological Therapeutics Market Analysis
Rare Diseases
Canada Acromegaly Therapeutics Market Analysis
Pharmaceuticals